Protein tyrosine phosphatase PTP1B is a critical regulator of signaling pathways controlling metabolic homeostasis, cell proliferation and immunity. In this study, we report that global or myeloid-specific deficiency of PTP1B in mice decreases lifespan. We demonstrate that myeloidspecific deficiency of PTP1B is sufficient to promote the development of acute myeloid leukemia Research.
It has been shown previously that PTP1B plays a key role in the pathogenesis of tumour development. Overexpression of PTP1B can be a driving factor in the pathogenesis of breast cancer (6, 12) , whereas deficiency has been shown to increase the invasiveness of prostate cancer (13) .
STAT3 over-expression and/or over-activation also plays a critical role in multiple tumorigenic processes (14) . Deletion of chromosome 20q (del(20q)) is a common chromosomal abnormality associated with myeloid neoplasms and the del(20q) involving PTPN1 deletion was observed in 8% of secondary acute myeloid leukaemia cases and 17% of myeloproliferative neoplasms. Given the poorly defined and often opposing roles that PTP1B and STAT3 play in the aetiology of inflammation and cancers, we sought to characterise the long-term implications of PTP1B deficiency and associated STAT3 hyperphosphorylation in myeloid cells that drive the pathogenesis of both conditions.
We report here that the absence of myeloid PTP1B (LysM-PTP1B -/-) in mice results in a shortened lifespan due to the late development of acute leukaemia. By contrast, heterozygous deficiency (LysM-PTP1B +/-) does not lead to development of leukaemia, suggestive that a complete deficiency of PTP1B is required for the phenotype. This recapitulates the shortened lifespan we observe in global PTP1B -/-mice.
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Methods:
Animal Studies:
All animal procedures were approved by the UK Home Office under The Animals (Scientific Procedures) Act 1986 (PPL60/3951). PTP1B -/-and wild type PTP1B +/+ littermates were maintained for lifespan studies at Beth Israel Deaconess Medical Center, Boston, USA (2) . PTP1B fl/fl mice (15) and mice expressing Cre under the LysM-promotor (LysM-PTP1B -/-) (16) were maintained for lifespan studies at the Medical Research Facility, Aberdeen, UK. Mice were housed and maintained at 22-24 o C on a 12 hour light-dark cycle, with free access to food and water on standard chow diet and aged to 24 months (104 weeks).
Bone Marrow Derived Macrophage (BMDM) preparation and treatment
BMDM were prepared from mononuclear phagocyte precursors flushed from femurs and tibias as previously described (9) . BMDM were stimulated with either 100ng/ml lipopolysaccharide (LPS) (InvivoGen) or 20 ng/ml IL-10 (Peprotech). In selected experiments, mature BMDM were pretreated with 5uM of Ruxolitinib (Selleck) before stimulation with LPS.
Adhesion Assays:
Adhesion assays were performed as previously described (17) . In brief, 96-well plates were precoated with 50 µg/ml collagen. BMDM (5 × 10 5 per well) were seeded and left to adhere for 30 minutes. Non-adherent cells were washed off; adherent cells stained with crystal violet, washed and lysed. OD595 value was measured in a plate reader OpsysMR (DYNEX Technologies).
Antigen presentation assays:
We used an OVA-peptide system, which assesses the presentation of the SIINFEKL OVA-peptide on MHC class I to the T cell reporter cell line B3Z. Mature BMDM were seeded in triplicates in 96-well plates ( 5 × 10 4 cells per well). Cells were left to adhere and incubated with the SIINFEKL peptide for 7
Haematoxylin and Eosin Staining:
Tissues were fixed in formaldehyde, embedded in paraffin, sectioned and stained with haematoxylin and eosin. Histological analysis on H&E stained sections was performed by an experienced histopathologist (MV).
Immunoblotting:
Tissues and cells were homogenized in radioimmunoprecipitation-assay buffer containing sodiumorthovanadate and protease inhibitors (9) . Proteins were separated by SDS-PAGE (4-12%) and transferred to nitrocellulose. Immunoblotting was performed using antibodies from Cell Signalling
Technologies, unless otherwise stated: p-STAT3 Y705, p-STAT3 S727, STAT3, p-P38 T108/Y182, P38, p-ERK T202/204, ERK, GAPDH, pSTAT5 Y694, STAT5 and PTP1B (Millipore). Immunoblots were visualized using enhanced chemilluminescence, and quantified using Bio-1D densitometry scanning software (PeqLab, UK).
Immunohistochemistry:
Immunohistochemistry was performed as previously described (9) . Briefly, tissues were fixed in formalin, embedded in paraffin, sectioned, dewaxed in Histoclear, rehydrated, subjected to antigen retrieval (10mM Trisodium Citrate HCl, pH6, 0.05% (v/v) Tween), quenched and blocked (TBS-Tween, 0.05% (v/v) Goat Serum). Primary antibody was incubated at optimal concentration followed by secondary HRP-conjugated antibody. DAB substrate was used for detection with a haematoxylin nuclear counterstain. Sections were visualized by light microscopy (Carl Zeiss Microscopy) and AxioVision 4.8 digital image processing software (Carl Zeiss Microscopy).
Gene Expression Analysis:
Tissues were homogenized in TriZol reagent (Sigma) and cDNA synthesis carried out from 1μg of RNA using a Tetro cDNA Synthesis Kit (Bioline 
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ChIP-seq analysis:
Detailed description can be found in Supplemental Methods. BMDM extracted from PTP1B fl/fl and LysM-PTP1B -/-mice aged 6 months were treated ± IL10 20ng/ml (Peprotech) for 4 hours(n=4/group).
ChIP was performed using the SimpleChIP Enzymatic Chromatin IP kit (Cell Signalling) according to manufacturer's instructions, with chromatin sheered to 200 bp and 10µl of STAT3 Mouse mAb #9139 per IP (Cell Signalling).
Microarray bioinformatics analysis:
Detailed description can be found in Supplemental Methods. PTP1B fl/fl and LysM-PTP1B -/-mice (n=5 and 4, respectively) were injected with 0.5 mg/kg LPS i.p. for 3 hours. Microarray was performed using Gene 2.0ST array (Affymetrix), according to manufacturer's instructions.
Data Analysis:
Data are expressed as mean ±SEM unless otherwise stated. Statistical analyses were conducted using one-way ANOVAs with Turkey post-hoc testing, two-way ANOVAs with Bonferroni post-hoc testing, two-tailed Student's t tests, or Kaplan-Meier analyses, as appropriate, using GraphPad Prism 5 software.
Research. Figure 2a&b )(n=12/genotype).
LysM-PTP1B -/-mice had increased total numbers of bone marrow cells between 4 and 12 months of age (Figure 1b ), but these numbers declined sharply after 12 months of age compared to that of PTP1B fl/fl mice.
LysM-PTP1B -/-mice develop acute myeloid-like leukaemia phenotype
The decline in total numbers of bone marrow cells with age could be indicative of the release of immature cells from the bone marrow; therefore the characteristics of circulating cells
were assessed. LysM-PTP1B -/-mice exhibited an increase in leukocytosis (Fig 1c-e) , with an increasing proportion of blast cells and 50% decrease in the percentage of neutrophils (Fig 1d) Table 4 )(23).
Upregulation of mTOR and amino acid sensing activators of mTOR, lamtor 4 and 5, provide a further link to these pathways since aberrant activation of the mammalian target of rapamycin complex 1 (mTORC1) is a common molecular event in cancer, by specifically activating bioenergetic and anabolic cellular processes (24) . In addition, Sirt3 and Sirt5 were upregulated and both of these protein deacetylase sirtuins have been reported to positively regulate mitochondrial fatty acid oxidation (25) . These results suggest a hallmark of cancer, i.e. metabolic reprogramming in the form of increased lipid metabolism is associated with tumour development in livers of LysM-PTP1B -/-mice.
Myeloid PTP1B deficiency alters expression of splenic and hepatic tissue cytokines
Given the changes in cell populations in splenic and hepatic tissue from LysM-PTP1B -/-mice with tumours, we investigated whether the expression levels of immunosuppressive genes were altered. Interleukin-4 (IL-4), an anti-inflammatory cytokine (26) , was found to be significantly 
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Constitutive activation of multiple STAT family members have been determined to be major pro-oncogenic drivers (30) and tyrosine-phosphorylated STATs are major substrates for PTP1B (9, 10, 31) . We have demonstrated previously that deletion of PTP1B can increase both STAT3 tyrosine phosphorylation and STAT3 expression levels in bone marrow derived macrophages (BMDM) (9) and dendritic cells (BMDC) (11) and we also demonstrate that total levels of STAT5 protein and mRNA increase in LysM-PTP1B -/-livers and spleens (Supplemental Figure 5a-f) .
To determine the level of STAT3 activity through DNA binding, ChIP-seq analysis was performed in BMDM from PTP1B fl/fl and LysM-PTP1B -/-mice, under basal and IL-10 stimulated conditions. There were relatively few STAT3 binding peaks in control mice of both genotypes (<200), but IL-10 treatment resulted in a >10-fold increase in STAT3 binding in total and in regions associated with genes (Fig 4a) . Motif analysis revealed the increase in STAT3 binding occurred at the canonical STAT3 binding-motif (TTCnnnGAA e.g. TTCCnGGAA) (Fig 4b) and also TTCC and GGAA half- Research. 
It has been robustly demonstrated that p38 induction can be required for IL-10 production in macrophages (33) , hence, we assayed culture media for TNF and IL-10 production following treatment with ruxolitinib (Figure 6j,k) . TNF secretion was inhibited upon PTP1B deficiency in LPSstimulated BMDM and this was reversed upon ruxolitinib treatment (Figure 6j) . Conversely, IL-10 production was significantly reduced by blockade of the JAK-STAT signalling pathway in LysM-PTP1B -/-BMDM (p<0.001) (Figure 6k) , thus, demonstrating that dysregulation of STAT3 signalling due to myeloid-PTP1B deficiency is the driving factor in the enhancement of IL-10 production in the LysM-
PTP1B
-/-model.
It was important to determine whether inhibiting STAT3 activity could reverse and restore the functional defects observed in LysM PTP1B -/-cells. We previously demonstrated that DCs in LysM-PTP1B -/-mice have altered functionality, with a decreased ability to prime antigen specific T cell responses and increased adherence in vivo in response to LPS stimulation (11). We now demonstrate that LysM-PTP1B -/-BMDM also display this phenotype, with a significant decrease in LysM-PTP1B -/-BMDM ability to activate B3Z reporter T cell model (p<0.001) (Figure 6l ). However, treatment with ruxolitinib decreases activation of B3Z T cells in both PTP1B fl/fl and LysM-PTP1B
-/-BMDM, indicating that suppression of the JAK-STAT pathway downregulates functions of both genotypes to equal levels ( Figure 6l ). In addition, DC from LysM-PTP1B -/-mice exhibited an increase in adhesion to collagen (11). We demonstrate that this phenotype is present in LysM-PTP1B
-/-BMDM and that treatment with ruxolitinib restores the phenotype of unstimulated LysM-PTP1B
-/-BMDM to that of control unstimulated PTP1B fl/fl BMDMs (Figure 6m ). These data demonstrate that inhibition of JAK-STAT pathway, leads to inability of BMDM to increase adhesion to collagen substrate following LPS stimulation, and suggest that changes in the functionality of LysM-PTP1B
-/-BMDM are JAK/STAT-driven.
Research. PTP1B has been suggested to play a role in both, colony stimulating factor 1 (CSF1) (7) signalling, and fms like tyrosine kinase (FLT-3) signalling (36) , which can regulate proliferation and mobilisation of myeloid cells from the bone marrow (37) . Both these molecules have been reported to signal through STAT3 (37, 38) , and thus activation of these pathways should be a focus of future studies.
Histological analysis of LysM-PTP1B -/-tissues revealed infiltration of leukemic cells into hepatic and lung tissues, with tumour development. The tumours contained cells with a high nuclear: cytoplasmic ratio, a common feature of malignant cells (39) . As the cell becomes malignant, this can affect packing of the nuclear material, often giving rise to large clumped heterochromatin and hypochromatic nuclei with wrinkled nuclear membranes (39), both of which are evident in the LysM-PTP1B -/-tumours.
LysM-PTP1B -/-mice exhibit an increase in IL-10 expression in BMDM (9) . We now report that in aged mice, the increase in IL-10 expression is systemic and found both, in serum and at mRNA level in multiple tissues. With respect to inflammatory metabolic disorders, such as T2DM, heightened IL-10 production may be advantageous, since T2DM is associated with inflammation- 
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mediated PTP1B upregulation in multiple tissues. However, long-term exposure has been suggested to contribute towards tumour development, by supressing natural tumour immunity (29) .
LysM-PTP1B
-/-myeloid cells exhibit hyperphosphorylation of STAT3 under normal homeostatic conditions (9), in both BMDM and dendritic cells, from 6 month old mice, suggesting that changes in STAT3 occur prior to development of leukaemia. STAT5 activation has been suggested to play a role in myeloproliferative neoplasms (19) . Importantly, STAT5 is not hyperphophorylated basally or upon LPS stimulation in LysM-PTP1B -/-BMDM. STAT3 is at the centre of multiple signalling cascades, and both, over-expression and constitutively active STAT3, are associated with multiple cancers, due to its anti-apoptotic and proliferative effects (28, (40) (41) (42) (43) .
Given that LysM-PTP1B +/-mice exhibit an increase in STAT3 mRNA and protein levels in the spleen and liver without the development of tumours, it is likely that that even some PTP1B mediated STAT3 exerts many of its pro-survival and proliferative effects via downstream effects in the B cell lymphoma family of proteins, including changing Bcl-6 and Bcl-2/Bcl-XL (pro and anti-apoptotic respectively) ratios, which can alter the survival of a cell (31) . The ratio of Bcl-6 to Bcl-2/Bcl-XL can be used as a prognostic marker for cancers and is correlated with poor survival (44) . We demonstrate that this ratio is skewed in favour of the anti-apoptotic Bcl-2 and Bcl-XL in LysM-PTP1B -/-mice, thus favouring cell survival. It has been established that enhanced survival due to increased Bcl-2 (45) is STAT3 dependent, and high levels of Bcl-2 can confer resistance to chemotherapy in myeloid leukaemias. Bcl-XL also protects cells against a number of cytotoxic insults, including induction of cytokine resistance (46) , and promotes cell survival (47) , and again high expression can confer a multidrug resistant phenotype (48) . It has been suggested that this is due to Bcl-XL mediated We propose that complete deficiency of PTP1B in myeloid cells results in the development of leukaemia through multiple mechanisms (Figure 5i ). An increase in bone marrow cellularity in young mice, coupled with increased survival and proliferation due to STAT3 mediated effects (potentially involving FLT3), increases the chance of secondary mutations. Meanwhile, the development of a systemic immunosuppressive environment through high IL-10 levels and inability of antigen presenting cells to prime immune responses may lead to a lack of immune surveillance.
This would be further exacerbated through the IL-10-STAT3 signalling axis, thus establishing a positive feedback loop to further drive unregulated proliferation and survival through imbalance of Bcl-6 and Bcl-2/Bcl-XL. In summary, our data demonstrate a tumour suppressive role for myeloid PTP1B and provide further evidence that PTP1B is a critical gene in the pathogenesis of del(20q) myeloid malignancies (19 
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